计算组织学人工智能预测晚期胰腺癌一线化疗选择的生物标志物开发与验证
本研究利用计算组织学人工智能平台,从H&E染色活检全切片图像提取定量组织形态学特征,开发并锁定预测氟嘧啶类(F-chemo)与吉西他滨类(G-chemo)一线化疗获益差异的GvF生物标志物。在包含477例患者(开发178例,验证299例)的多机构队列中验证,F-pref患者接受F-chemo的TNTD和OS均显著优于G-chemo,G-pref患者接受G-chemo的TNTD显著更优但OS无差异,生物标志物可预测治疗效应。
要点
- 基于H&E活检图像的人工智能GvF生物标志物可预测晚期PDAC一线化疗方案获益差异。
- F-pref患者接受F-chemo较G-chemo的TNTD和OS均显著改善。
- G-pref患者接受G-chemo的TNTD显著更优,但OS无显著差异。
核心结论
- 基于组织形态学的GvF生物标志物可预测晚期PDAC一线F-chemo与G-chemo的差异治疗获益。
- 该生物标志物可辅助晚期PDAC一线治疗的优化选择。
研究设计与样本
- 利用CHAI平台从H&E染色诊断活检全切片图像提取定量组织形态学特征。
- 多机构开发队列178例,独立验证队列299例(来自COMPASS和Know Your Tumor前瞻性研究),共477例。
- 开发队列中基于F-chemo与G-chemo患者间以TNTD衡量的差异结局相关特征生成连续评分,二分类为G-pref或F-pref,并锁定生物标志物和阈值。
- 验证队列以TNTD和OS评估差异治疗结局,并进行倾向评分加权分析。
主要发现
- 验证队列173例F-pref患者中,F-chemo较G-chemo的TNTD显著更优(P = .035;中位TNTD:F-chemo 8.6个月;G-chemo 7.5个月),OS亦显著更优(P = .003;中位OS:F-chemo 14.4个月;G-chemo 11.7个月)。
- 验证队列126例G-pref患者中,G-chemo较F-chemo的TNTD显著更优(P = .038;中位TNTD:F-chemo 7.2个月;G-chemo 9.6个月),但OS无差异(P = .5;中位OS:F-chemo 12.4个月;G-chemo 14.3个月)。
- 倾向评分加权分析中,生物标志物预测治疗效应(生物标志物-治疗交互作用TNTD P < .001;OS P = .005)。
- RNA亚型与TNTD和OS相关,但未预测差异治疗效应(P = .3)。
临床怎么用
- 对于晚期PDAC拟接受一线化疗者,可基于诊断活检H&E图像计算GvF评分以辅助选择F-chemo或G-chemo。
- GvF评分结果为F-pref时,优先考虑含氟嘧啶类方案;为G-pref时,优先考虑吉西他滨类方案。
局限性
- 验证队列来自前瞻性研究但非随机对照,治疗选择可能存在混杂,研究采用倾向评分加权分析。
- G-pref患者中G-chemo的OS优势未达统计学显著,F-pref和G-pref的OS获益不一致。
- RNA亚型未显示预测差异治疗效应的能力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Predictive biomarkers to guide selection of first-line chemotherapy for advanced pancreatic ductal adenocarcinoma (PDAC) are an unmet clinical need. This study used the Computational Histology Artificial Intelligence (CHAI) platform to develop and validate a histomorphology-based G-chemo versus F-chemo (GvF) biomarker that predicts benefit from first-line fluoropyrimidine-based (F-chemo) versus gemcitabine-based (G-chemo) regimens. METHODS: The CHAI platform extracted quantitative histomorphologic features from whole-slide images of hematoxylin and eosin-stained diagnostic biopsies. In a multi-institutional development cohort, features associated with differential outcomes as measured by time to next treatment or death (TNTD) between F-chemo-treated and G-chemo-treated patients produced continuous biomarker scores, which were dichotomized into G-pref or F-pref results. The biomarker and threshold were locked. An independent validation cohort from the prospective COMPASS and Know Your Tumor studies assessed differential treatment outcomes by TNTD and overall survival (OS). RESULTS: There were 477 patients (development: 178; validation: 299). In validation, among 173 F-pref patients, those treated with F-chemo had significantly better outcomes than G-chemo for both TNTD (P = .035; median TNTD: F-chemo 8.6 months; G-chemo 7.5 months) and OS (P = .003; median OS: F-chemo 14.4 months; G-chemo 11.7 months). Among 126 G-pref patients, G-chemo had significantly superior TNTD (P = .038; median TNTD: F-chemo 7.2 months; G-chemo 9.6 months), but no difference in OS (P = .5; median OS: F-chemo 12.4 months; G-chemo 14.3 months). In propensity score-weighted analysis, the biomarker predicted treatment effect (biomarker-treatment interaction TNTD P < .001; OS P = .005). RNA subtypes were associated with TNTD and OS but did not predict differential treatment effects (P = .3). CONCLUSION: The histomorphology-based GvF biomarker predicted differential treatment benefit of first-line GvF. This biomarker can guide optimal treatment selection for first-line therapy in advanced PDAC.
引用
- Hendifar AE, Krishna V, Krishna V, et al. Development and Validation of a Computational Histology Artificial Intelligence-Powered Predictive Biomarker for Selection of Chemotherapy in Advanced Pancreatic Cancer. J Clin Oncol. 2026. PMID: 41671529. doi:10.1200/JCO-25-02199
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。